JP Morgan's top five stocks for 2014

Should you consider any of these stocks?

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

JP Morgan's head of research, Paul Brunker, has revealed the investment bank's top five stocks for 2014.

According to the Australian Financial Review (AFR), the main theme Mr Brunker has adopted is a view that the Australia dollar is likely to fall next year as domestic growth fades, and a couple of stocks were picked to offer exposure to a pickup in developed world growth.

Currently, the US and Europe appear to be growing, albeit slowly, but that could gather momentum with ongoing stimulus measures in the US.

Additionally, Mr Brunker says that the investment bank is concerned that there is a lack of credible earnings growth among the big-cap sectors. The major banks have seen low credit growth over the past couple of years and that could continue. Our major resources companies are likely to struggle growing earnings, especially if the iron ore price falls, as many analysts are predicting.

On that basis, JP Morgan has picked Resmed (ASX: RMD), Brambles (ASX: BXB), Sims Metal Management (ASX: SGM), Coca-Cola Amatil (ASX: CCL) and Crown Resorts (ASX: CWN) as its stocks for 2014.

Resmed, Brambles and Sims would benefit from the Australian dollar falling substantially, as they generate a fair proportion of revenues offshore. Coca-Cola Amatil was picked because JP Morgan believes concerns over the company have been overdone, and Crown offers growth from emerging markets through its Asian casino joint venture, Melco Crown Entertainment.

Some of the stocks will likely do well if the Australian dollar falls and developed countries' economies pick up, but Sims Metal is not what we would regard as investment grade. In the past two years, Sims has reported a combined loss of close to $1 billion, despite revenues of over $16 billion. Additionally the company hasn't generated a return on equity above 7% since 2008, and has a total shareholder return of just 4.3% over the past 10 years. Cash in the bank would've beaten that and for far less risk.

Foolish takeaway

It will be interesting to see how these stocks perform in 2014, and we may have to revisit this article in early 2015 to see how they went.

Motley Fool writer/analyst Mike King owns shares in Resmed and Coca-Cola. You can follow Mike on Twitter @TMFKinga

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »